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Impact of an Antimicrobial Stewardship Program
Comprehensive Care Bundle on Management of
Candidemia
Allen Antworth, Curtis D. Collins, Anjly Kunapuli, Kristin Klein, Peggy Carver, Tejal Gandhi,
Laraine Washer, and Jerod L. Nagel
Study Objective. To analyze the impact of a comprehensive care bundle
directed by an antimicrobial stewardship team (AST) on the management
of candidemia.
Design. Single-center, quasi-experimental study.
Setting.A 930-bed academic hospital.
Patients. Seventy-eight patients with candidemia were evaluated; 41 patients
received the candidemia care bundle (AST group), and 37 did not (his-
torical control group).
Measurements and Main Results.A candidemia care bundle was developed
by an interdisciplinary AST, incorporating key elements from the Infectious
Diseases Society of America’s Clinical Practice Guidelines for the Manage-
ment of Candidemia. The AST made prospective recommendations in
accordance with the care bundle. Bundle elements were utilization of appro-
priate antifungal agents with appropriate duration of use, removal of intra-
venous catheters, repeat blood cultures, monitoring of time until clearance
of candidemia, and performance of ophthalmologic examinations. Compli-
ance with all candidemia care bundle elements was significantly higher in
the AST group versus the control group (78.0% vs 40.5%, p=0.0016).
Implementation of the care bundle significantly improved rates of ophthal-
mologic examination (97.6% vs 75.7%, p=0.0108), selection of appropriate
antifungal therapy (100% vs 86.5%, p=0.0488), and compliance with an
appropriate duration of therapy (97.6% vs 67.7%, p=0.0012). In addition,
the AST group had fewer excess total days of therapy beyond the recom-
mended duration than the control group (5 vs 83 total antifungal days).
Length of hospitalization (20 vs 21 days, p=0.9184), time until clearance of
candidemia (3 vs 3 days p=0.610), rate of persistent candidemia (22% vs
40.5%, p=0.126), and rate of recurrent candidemia (4.9% vs 5.4%, p=0.916)
were similar in the AST group versus the control group.
Conclusion.A comprehensive candidemia care bundle directed by our institu-
tion’s AST improved the management of patients with candidemia. We
encourage further exploration into the use of care bundles by ASTs as part
of their multifaceted approach to promoting appropriate antimicrobial utili-
zation and optimizing the management of patients with infectious diseases.
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The ultimate goal of antimicrobial steward-
ship programs is to improve patient care and
health outcomes; however, much of the existing
research surrounding stewardship programs has
focused on promoting appropriate utilization,
cost containment, and reduction in resistance
rates.1, 2 Development of novel ways in which
antimicrobial stewardship programs can facili-
tate optimal infection-related patient care is
needed,2 and utilization of comprehensive care
bundles by antimicrobial stewardship teams
have been proposed to improve care of
patients.3 Care bundles are used to systemati-
cally manage specific diseases to optimize qual-
ity of care by ensuring that all aspects of clinical
care are completed.3, 4 Various infection-related
care bundles have demonstrated improved man-
agement and outcomes of patients with sepsis,
Clostridium difficile infection, and ventilator-
associated pneumonia.5–7 To our knowledge, no
previously published reports have evaluated the
impact of a care bundle on the management of
patients with candidemia; thus, our objective
was to analyze the impact of a comprehensive
care bundle directed by our institution’s antimi-
crobial stewardship team (AST) on the manage-
ment of candidemia.
Methods
Study Design and Setting
This single-center, quasi-experimental study
was designed to evaluate the effectiveness of a
comprehensive care bundle, developed by the
institution’s AST, to increase compliance with
activities related to the overall management of
patients with candidemia. Management of candi-
demia was compared between the group receiv-
ing the care bundle and historical controls,
using a pretest-posttest design. Institutional
review board approval was obtained for this
study.
The study was conducted at the University of
Michigan Health System (Ann Arbor, MI), which
is a 930–licensed bed, level 1 trauma center
serving both adult and pediatric patients. The
trauma center reports approximately 45,000
inpatient hospital stays annually. The institu-
tion’s AST was established in 1997 and is com-
posed of four dedicated infectious disease
clinical pharmacy specialists and three infectious
diseases physicians. One pharmacist and one
physician from the AST are dedicated to stew-
ardship efforts in the pediatric population. In
addition to daily stewardship activities, phar-
macy team members provide other patient care
responsibilities, and team physicians have clinic
and consultation service commitments.
Patient Population
All patients with candidemia were identified
using the institution’s electronic medical record
and clinical microbiology reports. Eligible
patients included both adult and pediatric
patients who had one or more positive blood
cultures for Candida species during the two
study periods: a historical control period from
June 1, 2010–December 31, 2010, and an AST
intervention period from June 1, 2011–Decem-
ber 31, 2011. Patients who died during the
study were excluded from the primary analysis,
as these patients would not have the opportunity
to complete all the elements of the care bundle.
Data Collection
Data collection was accomplished by review
of the electronic medical records and included
information on demographics, microbiologic
parameters, antifungal therapy, removal and
replacement of intravascular catheters, ophthal-
mologic examinations, and other potential meta-
static foci or complicated infections. In addition,
data on the following clinical outcomes were
reported: length of hospitalization, time to clear-
ance of blood cultures, persistent blood cultures
for more than 72 hours, and recurrent candide-
mia within 4 weeks.
Historical Control Period
During the historical control period of this
study, our institution used several strategies for
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candidemia management. Clinical microbiology
laboratory personnel alerted the ordering clini-
cian to initial positive blood culture results, and
further management was deferred to the patient’s
physician. Institutional guidelines for the man-
agement of candidemia, which were available on
the hospital’s internal Web site and published
in an antimicrobial handbook, recommended
empiric fluconazole therapy for patients with
candidemia (yeast on Gram’s stain), except for
patients in an intensive care unit who were he-
modynamically unstable or who had recently
received azole therapy, an echinocandin was
then recommended as empiric therapy. Deescala-
tion to fluconazole was encouraged if the isolate
demonstrated susceptibility to fluconazole, and
the guidelines recommended ophthalmologic
examination and removal of intravascular cathe-
ters, if possible. Patients received infectious dis-
ease consultations at the clinician’s discretion.
The AST involvement in the historical group
consisted of reviewing patients who were
receiving antifungal agents (e.g., voriconazole,
posaconazole, echinocandins, and liposomal
amphotericin) which required prior authorization
based on the institution’s antimicrobial steward-
ship policy. The AST would determine if initial
therapy was appropriate according to institutional
criteria and followup on culture results to deter-
mine if deescalation was possible. The AST did
not provide recommendations on nonpharmaco-
logic management of comprehensive care bundle
elements.
Antimicrobial Stewardship Team Intervention
Period
In developing the comprehensive care bundle,
the AST identified key elements from the Infec-
tious Diseases Society of America’s Clinical
Practice Guidelines for the Management of Candi-
diasis.8 The team then recommended the follow-
ing activities as part of the bundle: selection of
appropriate antifungal therapy based on culture
and susceptibility results; removal of intravascu-
lar catheters; repeat blood cultures at least every
48 hours until negative; appropriate duration of
antifungal treatment; and ophthalmologic exami-
nation to evaluate Candida endophthalmitis.
During the AST intervention period, members
of the AST used real-time surveillance and clini-
cal–decision support software (TheraDoc, Inc.,
Salt Lake City, UT) to identify patients with can-
didemia. As in the historical control phase, the
patients’ physicians were notified by the micro-
biology laboratory of initial positive blood
culture results demonstrated yeast on Gram’s
stain. In addition, AST members received
real-time notification of positive culture results;
they were paged between 7 A.M. and 5 P.M. on
Monday through Friday and e-mailed during
off-hours and weekends during the intervention
period. Other than the addition of the TheraDoc
alerts in the AST period, there were no differ-
ences in testing or reporting of positive cultures
between the two periods evaluated.
A secure, Web-based data collection applica-
tion (REDCap, version 3.6.6; Biostat Interna-
tional, Inc., Nashville, TN) was used to track
patients with candidemia during the intervention
period. The database contained a checklist of
bundle elements and included a free-text func-
tion allowing for communication among AST
members. Patients were evaluated daily until all
bundle elements were completed or until the
patient died or was discharged from the hospital.
Active intervention by AST members included
education on candidemia management, recom-
mendations for antifungal selection and duration
of therapy, requests for repeat blood cultures,
and ophthalmologic examination, as well as
infectious disease consultation if there was con-
cern for metastatic foci of infection.
Successful compliance with individual care
bundle elements was defined by the AST. Appro-
priate antifungal therapy was defined as initia-
tion of therapy according to institutional criteria
within 72 hours of reporting antifungal suscepti-
bility to Candida, with time being measured
from susceptibility results to placement of
appropriate antifungal order. Due to lack of AST
coverage overnight and on weekends, the deci-
sion was made a priori to use 72 hours as the
cut-off period for initiation of appropriate ther-
apy. Fluconazole was considered appropriate
therapy unless the Candida isolate exhibited a
fluconazole minimum inhibitory concentration
(MIC) of 32 lg/ml or greater; or the patient was
allergic, intolerant, or had other contraindica-
tions to fluconazole. A alternative antifungal
agent was considered standard of therapy if the
patient had a concomitant fungal infection
requiring expanded-spectrum antifungal cover-
age. Treatment with high-dose fluconazole
(800 mg every 24 hrs in adults, or a renally
adjusted, equivalent dose) or another antifungal
agent susceptible to the isolate was considered
acceptable if the fluconazole MIC was revealed
as susceptible–dose dependent (MIC 16 lg/ml).
For the bundle element of removing intravenous
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catheters, compliance was considered successful
if the catheter was removed or replaced, or if
the clinician documented that there was no
alternative central venous access. Blood cultures
had to be repeated at least every 48 hours from
the time of the initial positive Gram’s stain until
the results were negative. The appropriate length
of antifungal therapy for uncomplicated candide-
mia from an infected intravenous catheter was
defined as 14 days after the first negative blood
culture, or at least 4 weeks for documented dis-
seminated disease. Ophthalmologic examinations
were to be performed on all patients unless they
were neutropenic, in which case, the examina-
tion was to be completed after resolution of
neutropenia (absolute neutrophil count
> 500 cells/mm3).
The AST also evaluated risk factors for poten-
tial metastatic foci of infection or complicated
infection (persistently positive blood cultures for
> 72 hrs, or the presence of a prosthetic heart
valve, vascular graft, or implantable pacemaker
or defibrillator) and, if identified, encouraged
the primary care team to consider an infectious
diseases consultation or additional testing to
evaluate for metastatic disease.
Statistical Analysis
Statistical analysis was performed with Graph-
Pad software (GraphPad Software, La Jolla, CA).
Data were evaluated using the v2 test for cate-
goric data and t tests for continuous data. Suc-
cessful compliance with the individual elements
of the candidemia care bundle was analyzed
using the Fisher exact test. A p value of 0.05 or
less was considered to indicate a statistically sig-
nificant difference.
Results
Seventy-eight patients with candidemia were
included in the study: 37 in the historical con-
trol group and 41 in the AST group. Patient
demographic and clinical characteristics were
similar between the groups (Table 1). The
majority of patients in both groups were in the
intensive care, solid organ transplantation, bone
marrow transplantation, or hematology-oncology
services. The predominant source of candidemia
was from intravenous catheters, and the most
commonly isolated Candida species were C. albi-
cans, C. glabrata, and C. parapsilosis. Empiric
micafungin and fluconazole therapy were similar
in both groups; 31.7% and 35.1 received
micafungin, and 65.9% and 54.1% received
fluconazole in the AST and control groups,
respectively. Patients with prosthetic heart
valves, vascular grafts, or implantable pacemak-
ers or cardioverter-defibrillators constituted
22% and 12% (p=0.4172) of the control and
AST groups, respectively. Documented dissemi-
nated disease was not significantly different
between the control and AST groups (43% vs
27%, p=0.15), of which ophthalmologic disease
was the most common site of dissemination
(22% vs 5%, p=0.553). Candida endocarditis was
identified in four patients: one in the AST group
and three in the control group.











41.3  24.3 (0–91) 48  22 (0–85)
Male 20 (54.1) 17 (41.5)
Service
Adults 30 (81.1) 36 (87.8)
Intensive care 15 (40.5) 22 (53.7)
Hematology-
oncology
2 (5.4) 4 (9.8)
Bone marrow
transplantation
1 (2.7) 0 (0)
Solid organ
transplantation
0 (0) 1 (2.4)
Pediatrics 7 (18.9) 5 (12.2)
Intensive care 4 (10.8) 2 (4.9)
Hematology-
oncology
3 (8.1) 0 (0)
Bone marrow
transplantation
0 (0) 0 (0)
Solid organ
transplantation
0 (0) 0 (0)
Candida species
albicans 18 (48.7) 17 (41.5)
glabrata 7 (18.9) 11 (26.8)
parapsilosis 3 (8.1) 7 (17.1)
tropicalis 1 (2.7) 2 (4.9)
lusitaniae 3 (8.1) 2 (4.9)
Other 4 (10.8) 0 (0)




25 (67.6) 31 (75.6)
Intraabdominal 4 (10.8) 3 (7.3)
Genitourinary 3 (8.1) 4 (9.8)
Other 5 (13.5) 3 (7.3)
Empiric antifugal therapy
Micafungin 13 (35.1) 13 (31.7)
Fluconazole 20 (54.1) 27 (65.9)
Other 4 (10.8) 1 (2.4)
Data are no. (%) of patients unless otherwise specified.
ap>0.05 for all comparisons between the groups.
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Originally, 52 and 47 patients were included
in the AST and control groups, respectively;
however, 11 patients (21.2%) in the AST group
and 10 patients (21.3%) in the control
group died before possible completion of all
bundle elements; thus, their data were excluded
from analysis. Effective antifungal therapy was
started within 24 hours of Gram’s stain results,
for all patients except two who died; they died
before the availability of Gram’s stain results and
antifungal therapy was never started. The med-
ian time from Gram’s stain until death was 4.0
and 4.5 days (p=0.61) in the AST and control
groups, respectively.
Compliance with all candidemia bundle ele-
ments was significantly higher in the AST group
than in the control group (78.0% vs 40.5%,
p=0.0016; Table 2). The AST group, compared
with the control group, had significantly
improved rates of ophthalmologic examination
(97.6% vs 75.7%, p=0.0108), selection of appro-
priate antifungal therapy after sensitivity testing
(100% vs 86.5%, p=0.0488), and appropriate
duration of therapy (97.6% vs 67.7%,
p=0.0012). The rates of intravenous catheter
removal (95.1% vs 86.5%, p=0.3494) and repeat
blood cultures at least every 48 hours until neg-
ative (85.3% vs 78.4%, p=0.6118) were higher
for the AST group, but they were not statistically
significantly different.
Initiation of antifungal therapy within
24 hours of a positive Gram’s stain occurred in
92.7% and 89.2% (p=0.702) in the AST and con-
trol groups, respectively. There were no deaths
in the patients who started antifungal therapy
more than 24 hours after a positive Gram’s stain.
The AST intervened to begin antifungal therapy
for 12 patients in the AST group, with nine of
those based on real-time alerts and three based
on culture review. Effective empiric therapy was
started in 97.5% and 97.3% (p>0.99) in the AST
and control groups, respectively. One patient in
each group received fluconazole 400 mg/day for
a C. glabrata bloodstream infection with suscep-
tible–dose dependent susceptibility to fluconaz-
ole, which was defined as inappropriate empiric
therapy. All seven patients in the AST group
who were candidates for deescalation were
appropriately changed from micafungin to fluco-
nazole, whereas deescalation in the control
group occurred in five of 10 patients (p=0.044).
Seven patients in the control group and one
patient in the AST group continued antifungal
therapy beyond the recommended duration,
which resulted in 83 and 5 days of excessive
antifungal therapy, respectively.
The most common reason for bundle noncom-
pliance in the AST group was failure to obtain
repeat blood cultures at least every 48 hours
until clearance of candidemia, despite reminders
by AST members to the primary care team in
each case. Other areas of noncompliance were
failing to perform an ophthalmologic examina-
tion after resolution of neutropenia and failure
to remove an intravenous catheter. Time to intra-
venous catheter removal after Gram’s stain
results was similar between both groups,
2.0 days in the AST group versus 1.9 days in the
control group.
The infectious disease service was consulted
in 73% of patients in the AST group and 76% in
the control group, and bundle compliance was
similar for both groups (69% vs 86%, p=0.21).
Pediatric patients in the AST group had signifi-
cantly improved compliance with all bundle ele-
ments compared with pediatric patients in the
control group (100% vs 14.3%, p=0.0152); all
five pediatric patients reviewed by the AST were
compliant, and one of seven pediatric patients in
the control group were compliant.









All bundle elements successfully completed 15 (40.5) 32 (78.0) 0.0016
Patients with more than 1 element not completed successfully 9 (24.3) 1 (2.4) 0.0108
Completion of individual elements
Appropriate therapy after culture and susceptibility results 32 (86.5) 41 (100) 0.0488
Intravenous catheter removed 32 (86.5) 39 (95.1) 0.3494
Blood cultures every 48 hrs until negative 29 (78.4) 35 (85.4) 0.6118
Appropriate duration of therapy 25 (67.6) 40 (97.6) 0.0012
Ophthalmologic examination performed 28 (75.7) 40 (97.6) 0.0108
Data are no. (%) of patients.
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No significant differences in length of stay,
time to clearance of candidemia, or the inci-
dence of recurrent candidemia were identified
(Table 3). A trend toward higher rates of persis-
tent candidemia occurred in the control group
than in the AST group (40.5% vs 22.0%,
p=0.126). The mean duration of candidemia was
relatively short in both groups (4.5 vs 5.2 days),
which may be due to the majority of patients
having uncomplicated intravenous catheter-
related infections. The rate of recurrent candide-
mia within 4 weeks of completion of therapy
was 5.4% and 4.9% in the control and AST
groups, respectively. One patient in the control
group with recurrent candidemia, occurring
20 days after hospital discharge, did not com-
plete two of the recommended bundle elements;
the patient did not have repeat cultures docu-
menting clearance of candidemia and received a
course of treatment of only 10 days.
Discussion
Our results demonstrated that an AST-imple-
mented comprehensive care bundle improved
the overall management of patients with candi-
demia by facilitating improvements in both
drug-therapy– and non–drug-therapy–related
aspects of care. Increased compliance with indi-
cators, such as ophthalmologic examinations
and intravenous catheter removal, showed that
our AST-managed care bundle optimized aspects
of care broader in scope than simply selection of
optimal drug.
In addition, we were able to make improve-
ments in drug-related indicators, which we sus-
pected were already well managed. We found
that several patients in the historical control
group received inappropriate antifungal therapy
as well as inappropriate duration of therapy.
These results highlight limitations to our previ-
ous approach to candidemia management, which
were passive in nature and heavily relied on
educational guidelines. As stated previously,
institutional guidelines during both study time
periods provided empiric therapy recommenda-
tions and directed antifungal recommendations.
In addition, AST members reviewed patients
receiving micafungin, voriconazole, and liposo-
mal amphotericin B as part of our prior authori-
zation process and likely facilitated deescalation
when appropriate. Care bundle implementation
and the associated improvements in our track-
ing, communication, and documentation affor-
ded us the opportunity to substantially improve
these aspects of patient care. After bundle imple-
mentation, all patients received appropriate anti-
fungal therapy after return of culture and
susceptibility data, and only a single patient
received an inappropriate duration of therapy.
The primary factor associated with reduced
mortality in patients with candidemia is initiation
of antifungal therapy within the first 24 hours
from the time a blood culture is drawn, which is
a suggested performance measure in the Infec-
tious Diseases Society of America’s candidiasis
guideline.8, 9 Although we excluded patients who
died from our analysis, as they may not have had
the opportunity to complete all bundle elements,
we evaluated the timing of initial antifungal ther-
apy in all patients. Equal percentages (~90%) of
patients who died in both groups received anti-
fungal therapy within 24 hours of Gram’s stain,
and, as expected, we were unable to detect a sig-
nificant difference in mortality. There are several
likely explanations. First, our historical high
compliance rate showed that the real-time notifi-
cations from the microbiology laboratory direc-
ted to the primary care services was already
relatively successful. Second, we acknowledge as
a process limitation in our strategy, that AST
members did not receive these real-time notifica-
tions on evenings or weekends, and following up
on real-time e-mail alerts was not required dur-
ing off hours. Rapid diagnostic tests for Candida
identification, such as peptide nucleic acid fluo-
rescence in situ hybridization (PNA FISH), were

















3 (2–5) 3 (1–4) 0.610
No. (%) of patients
with recurrent
candidemia
within 4 wks of
completing
therapy
2 (5.4) 2 (4.9) 0.916
No. (%) of patients
with persistent
candidemia
lasting > 72 hrs
15 (40.5) 9 (22.0) 0.126
IQR = interquartile range.
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not used at our institution during the time of this
study, which could improve the time to appro-
priate therapy. In one study, implementation of
PNA FISH demonstrated time to effective therapy
and reduced costs, but the sample size was too
small to detect significant reduction in mortality
in patients with candidemia.10
The quasi-experimental design of this study
has several limitations. First, there was no con-
current randomized control group during the
AST study period, which may have minimized
the chance of maturation effects and other
factors unknown to the study investigators. To
attempt to account for this, both the control
(before care bundle implementation) and inter-
vention (after care bundle implementation)
cohorts were studied during the same calendar
time frame (June–December), which would
allow a similar maturation process of medical
students, residents, and fellows responsible for
patient care at our large academic teaching insti-
tution. In the same way, seasonal effects should
be relatively similar given the chosen time peri-
ods for the two cohorts. Although randomiza-
tion is superior in methodology, it could have
added an additional confounder in this study,
given the monthly rotation of members of medi-
cal teams. With a randomized control group,
members of the medical team would likely pro-
vide care for patients in both groups during the
study period and may enforce the same bundle
elements on patients not randomized to active
intervention, which could ultimately affect the
study results.
Another limitation to this study was the small
sample size. Although we demonstrated signifi-
cant improvement in bundle compliance, no sig-
nificant differences were seen regarding clinical
outcomes. Complications, such as recurrent can-
didemia, persistent candidemia, and develop-
ment of disseminated candidiasis, did not occur
frequently enough to detect significant differ-
ences with our sample size. It is possible that
significant differences may have been seen if
more patients were included in the study. Any
method of documenting time to clearance of
candidemia could also be considered a limita-
tion; however, there was no significant differ-
ence seen in this area, and the method used
likely had little impact on time to clearance.
To our knowledge, this is the first study
describing the implementation of a comprehen-
sive care bundle by an AST targeted at manage-
ment of a specific disease state. The impact of a
care bundle by an AST to improve compliance
with quality indicators has been previously
reported,4 and investigators reported incorpora-
tion of an antimicrobial stewardship program as
part of a larger bundled strategy in the manage-
ment of a C. difficile outbreak.11 The candidemia
care bundle implemented by our AST used
workflow process changes and innovative tech-
nology resources to improve the quality of medi-
cal care delivered in a disease state associated
with high morbidity and mortality; as suggested
by previous researchers.3
Conclusion
A comprehensive care bundle developed and
implemented by our AST improved management
of patients with candidemia at our institution.
We encourage further exploration into the use
of care bundles by ASTs as part of their multi-
faceted approach to promoting appropriate anti-
microbial utilization and optimizing the
management of patients with infectious diseases.
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